Omeros (OMER) said Friday that clinical trial site activation for enrollment is underway for its phase 3 program evaluating zaltenibart as a possible treatment for paroxysmal nocturnal hemoglobinuria.
A total of 120 clinical sites across 30 countries have been chosen for participation in the zaltenibart phase 3 program, the company said, adding that data needed for submission of the biologics licensing application remains on track for Q4 of 2026
Omeros shares were 1.2% higher in recent trading.
Price: 9.21, Change: +0.11, Percent Change: +1.21
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。